The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...
The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback